Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2016

View Archived Issues

Merck describes promising adenosine receptor A2a antagonists for treating Parkinson's disease

DS Biopharma spins out new company Afimmune

Exosomes encapsulating Alzheimer's disease biomarkers can be detected in plasma

Regeneron Pharmaceuticals signs agreement with BARDA for MERS research

AstraZeneca discloses potent capsid-binding human rhinovirus inhibitor AZN-001

European Commission grants marketing authorization to Gilead's Truvada

Pfizer set to acquire Medivation

Final phase IIa trial results for the first topical gel formulation of minocycline, BPX-01

Novel MST1/2 inhibitor stimulates tissue repair and regeneration in vivo

FORMA Therapeutics discloses ubiquitin hydrolase inhibitors

Gilead begins phase III program for filgotinib in rheumatoid arthritis

Trillium Therapeutics patents EGFR inhibitors

Novo Nordisk divulges neuropeptide Y receptor agonists

Sanford-Burnham Medical Research Institute reports glucocorticoid receptor translocation inhibitors

Emmaus will submit NDA to the FDA for its sickle disease therapy

VBI Vaccines will continue enrollment on its phase I trial evaluating cytomegalovirus vaccine

FDA grants fast track designation to AZD-3293 for the treatment of Alzheimer's disease

Amylyx Pharmaceuticals completes USD 5 million series A financing round

EMA validates marketing authorization for Puma's neratinib

Intelgenx completes study of montelukast using the Versafilm delivery technology

Phase II results for vemurafenib in patients with BRAF[V600E]-positive papillary thyroid cancer

FORMA Therapeutics patents HDAC 6 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...